Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,deferredLongTermLiab,totalAssets,commonStock,retainedEarnings,otherAssets,cash,totalCurrentLiabilities,deferredLongTermAssetCharges,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,netReceivables,longTermDebt,accountsPayable,treasuryStock,otherStockholderEquity,shortTermInvestments,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,changeInCash,repurchaseOfStock,totalCashFromOperatingActivities,depreciation,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,issuanceOfStock,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,trailingAnnualDividendRate,trailingPE,trailingAnnualDividendYield,epsTrailingTwelveMonths,epsForward,currency,priceHint,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,marketCap,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,exchange,exchangeDataDelayedBy,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,shortName,market,marketState,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,compensationRisk,auditRisk,longBusinessSummary,city,phone,state,shareHolderRightsRisk,compensationAsOfEpochDate,governanceEpochDate,boardRisk,country,website,maxAge,overallRisk,address1,industry,address2
t0,INVA,634461000.0,69402800,,,129431000,62220000,94123000,5986000,85469000,79483000,79483000,,-4694000,,,,19736000,85518000,6035000,49000,49948000,,109695000,94123000,1261326000.0,391609000.0,634461000.0,121797000.0,1088290000.0,1014000.0,-627879000.0,196008000.0,282890000.0,3804000.0,74023000.0,24000.0,372933000.0,519325000.0,88974000.0,387728000.0,14000.0,,,,-26394000.0,-52000.0,-26394000.0,-21310000.0,-1686000.0,36403000.0,-25000.0,84107000.0,4000.0,4957000.0,-21285000.0,-18906000.0,,369129000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.32765526,15.05 - 15.385,15.26,0.0,0.0,32,40,finmb_24362,NasdaqGS,"Innoviva, Inc.",USD,718509,1299571,6.1000004,0.6623236,9.21 - 16.72,-1.4099989,-0.08433008,9.21,16.72,1443571200,1619625900,1635278400,1635796800,0.0,6.7444935,0.0,2.27,1.64,USD,2,1.66,9.222892,6.257,14.714857,0.5951433,0.040445063,12.954348,2.3556528,0.18184264,1062556928,9.335366,2.4468596,15,America/New_York,EDT,-14400000,NMS,0,False,False,15.31,1630526403,0.05000019,15.26,15.385,15.05,810873,"Innoviva, Inc.",us_market,PRE,0.6,,,16.72,9.21,14.71,12.95,718.51k,1.3M,69.4M,,87.1M,0.47%,71.41%,8.93M,13.05,34.40%,12.86%,8.55M,,,0.00,0.00%,,0.00%,"Sep 29, 2015","Sep 07, 2015",1241:1000,"Jun 02, 2014","Dec 30, 2020","Mar 30, 2021",73.65%,94.92%,21.73%,58.87%,343.63M,3.39,8.70%,335.01M,326.2M,253.09M,2.27,43.80%,282.89M,2.79,387.93M,55.68,98.04,6.26,323.74M,210.35M,Value,94010,Healthcare,5,8,8,"Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.",Burlingame,650 238 9600,CA,4,1609372800,1622505600,5,United States,http://www.inva.com,86400,5,1350 Old Bayshore Highway,Biotechnology,Suite 400
t-1,INVA,539912000.0,69402800,,,90758000,67925000,53903000,3770000,90257000,86487000,86487000,,-4651000,,,,15742000,90476000,3989000,219000,4271000,,75016000,53903000,1260900000.0,391733000.0,539912000.0,125253000.0,999570000.0,1014000.0,-722002000.0,219226000.0,246487000.0,6110000.0,93759000.0,28000.0,342058000.0,438258000.0,93931000.0,385517000.0,66000.0,,,,-315481000.0,-557000.0,-315481000.0,-2505000.0,2094000.0,-232706000.0,-9000.0,85280000.0,3000.0,-1781000.0,-2511000.0,25996000.0,15000.0,335948000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.32765526,15.05 - 15.385,15.26,0.0,0.0,32,40,finmb_24362,NasdaqGS,"Innoviva, Inc.",USD,718509,1299571,6.1000004,0.6623236,9.21 - 16.72,-1.4099989,-0.08433008,9.21,16.72,1443571200,1619625900,1635278400,1635796800,0.0,6.7444935,0.0,2.27,1.64,USD,2,1.66,9.222892,6.257,14.714857,0.5951433,0.040445063,12.954348,2.3556528,0.18184264,1062556928,9.335366,2.4468596,15,America/New_York,EDT,-14400000,NMS,0,False,False,15.31,1630526403,0.05000019,15.26,15.385,15.05,810873,"Innoviva, Inc.",us_market,PRE,0.6,,,16.72,9.21,14.71,12.95,718.51k,1.3M,69.4M,,87.1M,0.47%,71.41%,8.93M,13.05,34.40%,12.86%,8.55M,,,0.00,0.00%,,0.00%,"Sep 29, 2015","Sep 07, 2015",1241:1000,"Jun 02, 2014","Dec 30, 2020","Mar 30, 2021",73.65%,94.92%,21.73%,58.87%,343.63M,3.39,8.70%,335.01M,326.2M,253.09M,2.27,43.80%,282.89M,2.79,387.93M,55.68,98.04,6.26,323.74M,210.35M,Value,94010,Healthcare,5,8,8,"Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.",Burlingame,650 238 9600,CA,4,1609372800,1622505600,5,United States,http://www.inva.com,86400,5,1350 Old Bayshore Highway,Biotechnology,Suite 400
t-2,INVA,485556000.0,69402800,,,50487000,49316000,28218000,3254000,87684000,84430000,84430000,,-4603000,,,,8866000,88694000,4264000,1010000,-33943000,,41621000,28218000,1260447000.0,387384000.0,485556000.0,128708000.0,922256000.0,1014000.0,-775905000.0,238437000.0,479193000.0,3898000.0,109490000.0,33000.0,572041000.0,111745000.0,92150000.0,383350000.0,623000.0,,,,-8500000.0,428000.0,-8500000.0,-12000.0,-2270000.0,66046000.0,-12000.0,74558000.0,5000.0,-9748000.0,-2511000.0,52349000.0,15000.0,568143000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.32765526,15.05 - 15.385,15.26,0.0,0.0,32,40,finmb_24362,NasdaqGS,"Innoviva, Inc.",USD,718509,1299571,6.1000004,0.6623236,9.21 - 16.72,-1.4099989,-0.08433008,9.21,16.72,1443571200,1619625900,1635278400,1635796800,0.0,6.7444935,0.0,2.27,1.64,USD,2,1.66,9.222892,6.257,14.714857,0.5951433,0.040445063,12.954348,2.3556528,0.18184264,1062556928,9.335366,2.4468596,15,America/New_York,EDT,-14400000,NMS,0,False,False,15.31,1630526403,0.05000019,15.26,15.385,15.05,810873,"Innoviva, Inc.",us_market,PRE,0.6,,,16.72,9.21,14.71,12.95,718.51k,1.3M,69.4M,,87.1M,0.47%,71.41%,8.93M,13.05,34.40%,12.86%,8.55M,,,0.00,0.00%,,0.00%,"Sep 29, 2015","Sep 07, 2015",1241:1000,"Jun 02, 2014","Dec 30, 2020","Mar 30, 2021",73.65%,94.92%,21.73%,58.87%,343.63M,3.39,8.70%,335.01M,326.2M,253.09M,2.27,43.80%,282.89M,2.79,387.93M,55.68,98.04,6.26,323.74M,210.35M,Value,94010,Healthcare,5,8,8,"Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.",Burlingame,650 238 9600,CA,4,1609372800,1622505600,5,United States,http://www.inva.com,86400,5,1350 Old Bayshore Highway,Biotechnology,Suite 400
t-3,INVA,456907000.0,69402800,,,118116000,35905000,76844000,2596000,78387000,75791000,75791000,,-4561000,,,,19891000,78946000,3155000,559000,42325000,,98225000,76844000,1260017000.0,386807000.0,456907000.0,132164000.0,879619000.0,1015000.0,-804123000.0,250776000.0,413147000.0,5414000.0,118348000.0,37000.0,500193000.0,128613000.0,82402000.0,381230000.0,195000.0,-2000.0,-2000.0,3999000.0,-7000000.0,73000.0,-7000000.0,-11628000.0,2772000.0,61166000.0,-17000.0,79794000.0,2000.0,-268000.0,-11808000.0,-5163000.0,197000.0,494779000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,0.32765526,15.05 - 15.385,15.26,0.0,0.0,32,40,finmb_24362,NasdaqGS,"Innoviva, Inc.",USD,718509,1299571,6.1000004,0.6623236,9.21 - 16.72,-1.4099989,-0.08433008,9.21,16.72,1443571200,1619625900,1635278400,1635796800,0.0,6.7444935,0.0,2.27,1.64,USD,2,1.66,9.222892,6.257,14.714857,0.5951433,0.040445063,12.954348,2.3556528,0.18184264,1062556928,9.335366,2.4468596,15,America/New_York,EDT,-14400000,NMS,0,False,False,15.31,1630526403,0.05000019,15.26,15.385,15.05,810873,"Innoviva, Inc.",us_market,PRE,0.6,,,16.72,9.21,14.71,12.95,718.51k,1.3M,69.4M,,87.1M,0.47%,71.41%,8.93M,13.05,34.40%,12.86%,8.55M,,,0.00,0.00%,,0.00%,"Sep 29, 2015","Sep 07, 2015",1241:1000,"Jun 02, 2014","Dec 30, 2020","Mar 30, 2021",73.65%,94.92%,21.73%,58.87%,343.63M,3.39,8.70%,335.01M,326.2M,253.09M,2.27,43.80%,282.89M,2.79,387.93M,55.68,98.04,6.26,323.74M,210.35M,Value,94010,Healthcare,5,8,8,"Innoviva, Inc. engages in the development and commercialization of pharmaceuticals. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.",Burlingame,650 238 9600,CA,4,1609372800,1622505600,5,United States,http://www.inva.com,86400,5,1350 Old Bayshore Highway,Biotechnology,Suite 400
